The role telomeres and telomerase play in the initiation and progression of human cancers has been extensively evaluated. 
Introduction
Telomeres are nucleoprotein complexes located at the extreme ends of eukaryotic chromosomes [1] . In normal human somatic cells, telomeres comprise 5-12 kb of the repeating hexanucleotide DNA sequence, TTAGGG [2, 3] . Numerous proteins are associated with these repetitive regions. The Shelterin complex, a core set of six proteins integral for telomere function, is composed of telomeric repeat binding factor (TRF)1, TRF2, protection of telomeres 1 (POT1), TRF interacting protein 1 (TIN2), repressor/activator protein 1 (RAP1) and TPP1 [4, 5] . The telomere complex primarily functions to mask double strand break DNA damage signals at telomeres, inhibit exonucleolytic degradation and prevent chromosomal fusions [6, 7] .
Telomeres can be critically shortened by incomplete replication of the lagging strand during DNA synthesis, known as the 'endreplication problem' [8, 9] . Through this process, each telomeric end shortens by approximately 50-100 base pairs during each successive cell division. Other known mechanisms leading to telomere loss include oxidative DNA damage [10, 11] and alterations of Shelterin proteins [12] . In normal somatic cells, significant telomere shortening leads to p53-dependent senescence or apoptosis [13, 14] . As a result, there is a limited number of population doublings a somatic cell may undergo before entering a senescent state. In cancer cells, these cell cycle checkpoints are abrogated, for example through mutations in tumour suppressor proteins. Consequently, unchecked cellular proliferation continues and genomic instability may ensue via chromosomal breakage-fusion-bridge cycles [15] .
In the vast majority (85-90%) of human cancers, telomere length appears to be maintained, or actively lengthened, through up-regulation of the enzyme telomerase. Telomerase is a reverse transcriptase that has the ability to synthesize new telomere DNA using an internal RNA template [1, 16, 17] [23] . [24, 25] and haematological malignancies [26, 27] . Here, we critically assess whether measurements of telomere lengths and/or telomerase levels will be useful as diagnostic markers for solid tumours. Due to space limitations, we focus predominantly on two common malignancies, breast and prostate cancer, and provide specific examples for other cancer types. [33] , slot blot assay [34, 35] , quantitative telomere-specific PCR (Q-PCR) [36, 37] and single telomere length analysis (STELA) [38] . Likewise [92] . In comparison to cytological preparations, Ͼ90% of breast cancers were telomerase positive, whereas, only a small fraction of benign breast lesions were positive for telomerase activity [93, 94] [112] .
The basic biology of telomeres and telomerase has been a focus of research for decades and mounting evidence demonstrates the crucial role telomere biology plays in the initiation and progression of carcinogenesis. Previous reviews have discussed the potential prognostic significance of telomere and telomerase measurements in solid tumours

Methods for telomere length and telomerase detection
Numerous methods have been developed to measure either actual telomere length or total relative telomere content, a proxy for mean length. These methods include terminal restriction fragment (TRF) Southern blot analysis [28, 29], quantitative fluorescence in situ hybridization (Q-FISH) [30-32], Flow-FISH
Other cancer types
As with breast and prostate cancer, telomerase activity or hTERT expression is present in the vast majority of solid tumours and has proved to be a marker of malignancy [113] . However, telomerase activity or hTERT expression has been shown to be present in some normal tissues and benign conditions. Due to the size of the field, the reader is directed to other comprehensive reviews discussing the potential clinical utility of using telomerase as a diagnostic marker in cancer in general [76] or within specific tumour types [114, 115] .
To provide a specific example, the detection of telomerase by non-invasive means such as analysing urine or other bodily secretions seems to be potentially useful some cancer types, in particular for bladder cancer [116, 117] [120] and across multiple other cancer types [121] . Likewise, genomic amplification of the TERC gene, which codes for hTR, has been associated with the development of invasive carcinomas, for example in lung cancer [122] , but most notably has been associated in the development of cervical cancer and may aid in the diagnosis of low-grade lesions when combined with cytology [123] [124] [125] [4] . At this point, the telomere no longer inhibits the DNA damage response pathway and is prone to telomere fusions via the non-homologous end joining DNA repair pathway [7] . Such [133] . More recently, a large-scale genome sequencing study revealed that pancreatic cancer acquires genomic rearrangements consistent with telomere dysfunction [134] . Additionally, telomere dysfunction resulting from telomere shortening can induce tetraploidization that drives tumorigenesis [135] .
. A case-control study comparing patients with confirmed bladder cancer and healthy controls analysed telomerase activity from urine samples. Using an arbitrary cut-off value, Sanchini and colleagues reported a 90% sensitivity and a 88% specificity with similar patterns observed in low-grade tumours [118]. These preliminary results seem promising, but caution must be taken because the presence of acute or chronic inflammation may affect the telomerase activity measurements. Nevertheless, the non-invasive evaluation of telomerase activity in urine may provide additional diagnostic information, independent of routine cytology and most importantly may identify low-grade tumours, which are difficult to identify by cytologi
Future directions
An exciting new area of ongoing research focuses on the assessment of telomere dysfunction, rather than telomere length alone, as a potential marker in cancer. In general, the telomere is 'capped', or functional, when the Shelterin complex is bound to the telomere, protecting the end of the chromosome from being recognized as a double-strand break. However, when the telomere is no longer protected, then the telomere is considered 'uncapped', or dysfunctional
Although [139] . New investigations on the cellular consequences of short telomeres have highlighted the importance of the induction of the DNA damage response pathway. Telomere-dysfunction induced foci can be visualized by the accumulation of ␥H2AX at the telomere [140] . Ultimately, it is hoped that further insights into the induction of the DNA damage response at the telomere will provide future avenues of study that may provide translational utility.
Although previous investigations have assessed telomere shortening in cancer cells, these length measurements have been considered a proxy for telomere dysfunction. The schematic in Figure 1 highlights 
